4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

10-Q - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

424B4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

EFFECT - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

S-1 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects.SARASOTA, Fla., July 15, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in its upcoming Phase 2a clinical trial. "These preclinical r

Company highlights its differentiated Bisphosphocin® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance developmentSARASOTA, Fla., July 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation designed to encourage the development of novel therapies t

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD

Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU programSARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has accepted the position of Study Chair for the Company's Phase 2a clinical trial evaluating Nu-3 for the treatment of infected diabe

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

New patent enhances global IP footprint and pipeline expansion opportunitiesSARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.

SARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will present at the Life Sciences Virtual Investor Forum on June 25, 2026. Presentation Details:Event:Life Sciences Virtual Investor ForumDate/TimeJune 25, 2026, at 11:30, AM EDTWebsiteRegistration Link"We look forward to presenting Lak

Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patentsSARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively.

Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers (iDFU) designed to reduce the risk of antimicrobial resistance (AMR).

Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU marketSARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for locally treatable infectious diseases called the Bisphosphocin® class, today announced that it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization (CRO) for its upcoming Phase 2 clinical program of Nu-3, the Company's lead Bisphosphocin® product for the

Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance